A study compared semaglutide and tirzepatide in individuals with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) without diabetes. The study utilized national claims data to emulate a trial.
Study Design and Patient Population
Inclusion criteria specified a BMI of 27 or greater with an ASCVD diagnosis, continuous insurance coverage, and no prior GLP-1 receptor agonist or obesity medication use. The primary outcome was a composite of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, heart failure hospitalization, unstable angina, coronary revascularization, and mortality.
Key Clinical Findings
Hazard ratios were estimated using Cox models with inverse probability weighting. The analysis found a non-significant difference in the risk of revised 5-point MACE between the two treatments. Secondary outcomes, including revised 3-point MACE and individual endpoints, also showed no significant difference.
Sensitivity analyses were performed, highlighting the impact of early events, off-label use, analytic approach, and outcome definition on the results. The study indicated that among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.